PLT Health Solutions and Laila Nutraceuticals launched a botanically based ingredient that provides a range of clinically supported benefits for athletes and the active/sports nutrition consumer called RipFACTOR Muscle Accelerator.
PLT Health Solutions (Morristown, NJ) and Laila Nutraceuticals launched a botanically based ingredient that provides a range of clinically supported benefits for athletes and the active/sports nutrition consumer called RipFACTOR Muscle Accelerator. The ingredient is available in a standard and a neutral tasting water-dispersible form.
“After a seven-year, multi-million-dollar development process involving in-depth screening of hundreds of botanicals, we are proud to deliver a breakthrough ingredient that can significantly and rapidly increase both upper and lower body strength and endurance as well as significantly increase muscle size, all in a low-dosage format,” said Seth Flowerman, president and CEO of PLT Health Solutions, in a press release. “Offering two dosage levels enables formulators to develop targeted SKUs for both emerging and performance athletes. RipFACTOR is already being developed as a hero ingredient in a range of leading brands in the active/sports nutrition market. Because it enhances strength and endurance in workouts — and builds muscle mass — it is a natural fit in the bodybuilding segment for pre-workout, muscle building, and testosterone boosters, in addition to general performance applications for competitive sports, endurance sports and fitness training.”
Two clinical studies were performed to determine its efficacy. The first study — an eight-week randomized, double-blind, placebo-controlled clinical study — featured young adult males who were familiar with weight training and had at least six months of experience with resistance exercises. Improvements in strength, endurance, and muscle size were seen throughout the study period. A statistically significant increase in both upper and lower body muscle strength were seen as early as 14 days compared to placebo.
A second study was conducted in 2019. This study examined two different dose levels—a performance and an ultra-performance dose. An efficiency model design was employed by including a second placebo group that followed a double exercise regimen. Subjects taking RipFACTOR demonstrated gains exceeding the placebo group doing twice the exercise. Subjects taking the performance dose also demonstrated similar strength and endurance benefits to subjects doing twice the amount of exercise. At the ultra-performance dose, the strength and endurance gains were significantly better than subjects completing twice the exercise volume. Improvements in testosterone and cortisol levels for the RipFACTOR group compared to the placebo groups provided a testosterone to cortisol ratio that favors anabolism and could be partially responsible for the muscle growth and strength benefits. Manuscripts for both studies will be submitted for publication in 2020.
“There really isn't anything else on the market today that drives significant gains in strength as early as two weeks, particularly with a dose less than one gram,” said Barbara Davis, head of clinical & regulatory sciences for PLT, in a press release. “RipFACTOR supports improved physical performance and faster results for a broad range of consumers. For formulators, the clinical work provides a broad range of tools to communicate the range of benefits to consumers – with messaging on physiological and performance improvements every step of the way.”